{"nctId":"NCT00421928","briefTitle":"Tapentadol (CG5503)","startDateStruct":{"date":"2007-01"},"conditions":["Osteoarthritis, Knee","Pain"],"count":1030,"armGroups":[{"label":"001","type":"EXPERIMENTAL","interventionNames":["Drug: tapentadol (CG5503)"]},{"label":"002","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: oxycodone"]},{"label":"003","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"oxycodone","otherNames":[]},{"name":"placebo","otherNames":[]},{"name":"tapentadol (CG5503)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients diagnosed with osteoarthritis of the knee based on the American College of Rheumatology (ACR) criteria and functional capacity class of I-III\n* patients taking analgesic medications for at least 3 months prior to screening and/or dissatisfied with their current therapy\n* Patients requiring opioid treatment must be taking daily doses of opioid-based analgesic, equivalent to \\<160 mg of oral morphine\n* baseline score of greater than or equal to 5 on an 11-point numerical rating scale, calculated as the average pain intensity during the last 3 days prior to randomization.\n\nExclusion Criteria:\n\n* History of alcohol and/or drug abuse in Investigator's judgement\n* history of significant liver insufficiency\n* chronic hepatitis B or C, or HIV, presence of active hepatitis B or C within the past 3 months\n* life-long history of seizure disorder or epilepsy\n* history of malignancy within past 2 years, with exception of basal cell carcinoma that has been successfully treated\n* uncontrolled hypertension\n* patients with severely impaired renal function\n* patients with moderate to severly impaired hepatic function or with laboratory values reflecting inadequate hepatic function","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline of the Average Pain Intensity Based on an 11-point Numerical Rating Scale(NRS) Over the Last Week of the Maintenance Period at Week 12.","description":"For this twice daily pain assessment, the subjects were to indicate the level of pain experienced over the previous 12 hours on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated \"no pain\" and a score of 10 indicated \"pain as bad as you can imagine\".","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.0","spread":"2.39"},{"groupId":"OG001","value":"-2.6","spread":"2.38"},{"groupId":"OG002","value":"-2.2","spread":"2.54"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Western Ontario McMaster Questionnaire (WOMAC) Assessing Pain, Disability and Joint Stiffness of the Knee Over the Last Week of the Maintenance Period at Week 12","description":"Change from baseline to Week 12 of WOMAC Global Score: WOMAC is measure with a Likert ordinal scale from 0-4 with lower scores indicating lower levels of symptoms or physical disability","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"0.82"},{"groupId":"OG001","value":"-1.1","spread":"0.87"},{"groupId":"OG002","value":"-0.9","spread":"0.84"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Sleep Latency Time in Hours Over the Last Week of the Maintenance Period at Week 12.","description":"A Sleep Questionniare addressed the following question: \"How long after bedtime/lights out did you fall asleep last night (hours)?\" 12 week endpoint-mean changes from baseline at endpoint for sleep latency. Decrease in time(hours) indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"2.8"},{"groupId":"OG001","value":"0.1","spread":"1.81"},{"groupId":"OG002","value":"0.3","spread":"2.72"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Reported Very Much Improved or Much Improved From Baseline in Patient Global Impression of Change Over the Last Week of the Maintenance Period at Week 12","description":"Ordinal measure indicating change from start of treatment (on a scale of 7 = Very much worse to 1 = Very much improved)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.1","spread":null},{"groupId":"OG001","value":"37.7","spread":null},{"groupId":"OG002","value":"32.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Distribution of Time to Treatment Discontinuation Due to Lack of Efficacy","description":"The median time to treatment discontinuation due to lack of efficacy from baseline to endpoint","paramType":"NUMBER","dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change From Baseline in EuroQol-5 (EQ-5D) Health Status Index to Week 12","description":"Change from baseline to end point in EuroQol-5 (EQ-5D) Dimension Questionnaire. A higher score indicates an improvement in health in the Health Status Index. The EQ-5D is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating \"full health\" and 0 representing dead","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.26"},{"groupId":"OG001","value":"0.5","spread":"0.28"},{"groupId":"OG002","value":"0.5","spread":"0.29"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Responder Analysis 50% Improvement to Week 12","description":"Defined by the percentage of subjects achieving at least 50% improvement from baseline in the primary endpoint based on the 11-point NRS at week 12. For this twice daily pain assessment, the subjects were to indicate the level of pain experienced over the previous 12 hours on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated \"no pain\" and a score of 10 indicated \"pain as bad as you can imagine\".","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.0","spread":null},{"groupId":"OG001","value":"17.3","spread":null},{"groupId":"OG002","value":"24.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":344},"commonTop":["Nausea","Constipation","Headache","Dizziness","Somnolence"]}}}